Evaluating Safety and Tolerability of BI 3802876 Infusions in Adults with Compensated Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis

What this Trial Is About

Researchers are studying adults with a confirmed liver condition called compensated cirrhosis caused by Metabolic Dysfunction-Associated Steatohepatitis MASH. The purpose is to assess how well a new medicine named BI 3802876 is tolerated and how the body processes different doses of this drug. BI 3802876 is being developed to improve liver health in people with this condition. Participants are randomly assigned to one of three dose groups, with a chance to receive either BI 3802876 or a placebo that looks like the medicine but has no active ingredient. The medicine is given as an infusion into a vein. The study lasts about six months, during which participants visit the study site 12 times. They receive the study medicine at two of these visits. During the study, doctors will monitor participants for any health problems and take blood samples to check how the body handles BI 3802876. They will compare results between the different dose groups and the placebo group. The main outcome is to observe any adverse events over a period of up to 134 days.

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)